MedPage Today June 5, 2024
— “Even with some variation, there’s still reasonably good protection”
An FDA advisory committee voted unanimously, 16-0, Wednesday to recommend that the COVID-19 vaccines for the 2024-2025 season target the JN.1 strain of the virus.
“From my review of the data, it appeared that the newer variants that are appearing — KP.2, KP.3, and maybe some others that are coming up — the potential for immunogenicity from a JN.1 vaccine to cover those variants seems to be pretty good,” said Archana Chatterjee, MD, PhD, of Rosalind Franklin University of Medicine and Science in Chicago. “Antigenically they are close, and from the experience we had with [the] XBB [strain], it appears even with some variation, there’s still reasonably good protection. So...
Today's Sponsors
Today's Sponsor